Cover Image
市場調查報告書

Advaxis, Inc. - 製品產品管線分析

Advaxis, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 226293
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
Advaxis, Inc. - 製品產品管線分析 Advaxis, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月13日 內容資訊: 英文 82 Pages
簡介

Advaxis, Inc.是臨床開發階段生技企業、獨立開發Lm- LLO免疫療法藥物創藥、開發、商品化。以自家公司製品為基準、強化癌症免疫系統、開發對各部位癌症治療有效的疫苗。

本報告針對Advaxis, Inc. 治療藥開發產品管線現況與各開發階段比較分析、藥劑標的、作用程制、用藥方式、分子種類分類治療藥評價、最新企業新聞與發表、後期階段與中止計畫相關情報。

Advaxis, Inc.基本情報

Advaxis, Inc.概要

  • 主要情報
  • 企業情報

Advaxis, Inc.:R&D概要

  • 主要治療範圍

Advaxis, Inc.:產品管線回顧

  • 開發階段分類產品管線製品
  • 單劑製品

Advaxis, Inc.:產品管線製品概況

  • 最終階段產品管線製品
    • 第III期製品/併用療法模式
  • 治療階段產品管線製品
    • 第I期製品/併用療法模式
  • 初期階段產品管線製品
    • 前臨床階段製品/併用療法模式

Advaxis, Inc.:藥劑檔案

  • ADXS-HPV
  • ADXS-HER2
  • Adxs-LmddA159
  • ADXS-PSA
  • Bivalent Therapy for Cancer
  • Drug Targeting PSCA for Prostate Cancer
  • Lm-LLO-CA9
  • Lm-LLO-CD-105
  • Lm-LLO-CEA
  • Lm-LLO-FAP
  • Lm-LLO-Flk-1
  • Lm-LLO-HER2-CA9
  • Lm-LLO-HMW-MAA-C
  • Lm-LLO-IL-13R Alpha2
  • Lm-LLO-ISG-15
  • Lm-LLO-PSA-HMWMAA
  • Lm-LLO-WT-1
  • Lovaxin S

Advaxis, Inc.:產品管線分析

  • 標的分類
  • 用藥方式分類
  • 分子種類分類

Advaxis, Inc.:最近產品管線動向

Advaxis, Inc.:暫停計畫

Advaxis, Inc.:總公司與分公司所在地

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08019CDB

Summary

Global Markets Direct's, 'Advaxis, Inc. - Product Pipeline Review - 2016', provides an overview of the Advaxis, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Advaxis, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Advaxis, Inc.
  • The report provides overview of Advaxis, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Advaxis, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Advaxis, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Advaxis, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Advaxis, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Advaxis, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Advaxis, Inc. Snapshot
    • Advaxis, Inc. Overview
    • Key Information
    • Key Facts
  • Advaxis, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Advaxis, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Advaxis, Inc. - Pipeline Products Glance
    • Advaxis, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Advaxis, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Advaxis, Inc. - Drug Profiles
    • axalimogene filolisbac
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADXS-HER2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADXS-PSA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Adxs-LmddA159
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADXS-NEO
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADXS-TNBC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lm-LLO-CA9
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lm-LLO-CD105A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lm-LLO-Flk1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lm-LLO-HMWMAAC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lm-LLO-ISG15
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lovaxin S
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target CEA for Ovarian Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target FAP for Breast and Colorectal Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target HER2 and CA9 for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target Her2 and HMWMAA for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target IL-13R Alpha2 for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target PSA and HMWMAA for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target PSCA for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target WT1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Advaxis, Inc. - Pipeline Analysis
    • Advaxis, Inc. - Pipeline Products by Target
    • Advaxis, Inc. - Pipeline Products by Route of Administration
    • Advaxis, Inc. - Pipeline Products by Molecule Type
  • Advaxis, Inc. - Recent Pipeline Updates
  • Advaxis, Inc. - Dormant Projects
  • Advaxis, Inc. - Company Statement
  • Advaxis, Inc. - Company Statement
  • Advaxis, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Advaxis, Inc., Key Information
  • Advaxis, Inc., Key Facts
  • Advaxis, Inc. - Pipeline by Indication, 2016
  • Advaxis, Inc. - Pipeline by Stage of Development, 2016
  • Advaxis, Inc. - Monotherapy Products in Pipeline, 2016
  • Advaxis, Inc. - Phase II, 2016
  • Advaxis, Inc. - Phase I, 2016
  • Advaxis, Inc. - Preclinical, 2016
  • Advaxis, Inc. - Pipeline by Target, 2016
  • Advaxis, Inc. - Pipeline by Route of Administration, 2016
  • Advaxis, Inc. - Pipeline by Molecule Type, 2016
  • Advaxis, Inc. - Recent Pipeline Updates, 2016
  • Advaxis, Inc. - Dormant Developmental Projects,2016

List of Figures

  • Advaxis, Inc. - Pipeline by Top 10 Indication, 2016
  • Advaxis, Inc. - Pipeline by Stage of Development, 2016
  • Advaxis, Inc. - Monotherapy Products in Pipeline, 2016
  • Advaxis, Inc. - Pipeline by Top 10 Target, 2016
  • Advaxis, Inc. - Pipeline by Route of Administration, 2016
  • Advaxis, Inc. - Pipeline by Molecule Type, 2016
Back to Top